Given the high vascular density and overexpression of vascular endothelial growth factor (VEGF) in GBM, anti-angiogenic therapy with agents such as bevacizumab has demonstrated efficacy in symptom management and radiographic response, though survival benefits remain limited [18]. Here, VEGFA is linked to glioblastoma.